This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1352458508095731v1 1352458508095731v2 15/1/68    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Niklas, A Articles by Then Bergh, F Search for Related Content PubMed PubMed Citation Articles by Niklas, A Articles by Then Bergh, F Social Bookmarking                         What's this?

Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency

¹ Klinik und Poliklinik für Neurologie, Universität Leipzig, Leipzig, Germany; Translational Centre for Regenerative Medicine (TRM-Leipzig), Universität Leipzig, Leipzig, Germany
² Klinik und Poliklinik für Neurologie, Universität Leipzig, Leipzig, Germany

^* To whom correspondence should be addressed.

	Abstract

Objective

Visual evoked potentials (VEP) may be suitable surrogate outcome measures in multiple sclerosis (MS) remyelination trials. The extent of spontaneous changes of subclinically delayed VEP is unknown, whereas VEP improve after acute optic neuritis (ON).

Methods

In all, 124 patients with three VEP recordings at least 3 months apart: 71 patients with MS who had never suffered clinical ON; 53 patients with ON (isolated ON or ON as an attack of MS at first recording). Latencies of P100 were analyzed by multivariate analysis of variance.

Results

Eyes of patients with MS had a mean P100 latency of 110.2 ms, worsening mildly over time (n = 104 eyes, P = 0.022). MS patients' eyes with subclinical demyelination (delayed P100 latency at first recording >116 ms) showed no significant evidence of remyelination (n = 24 eyes, P = 0.27). By contrast, in ON patients' affected eyes, mean P100 latency decreased (P = 0.001), whereas unaffected eyes remained stable (P = 0.26). Clinically non-affected eyes from both diagnostic groups with subclinically prolonged latencies remained stable (n = 32: mean P100 at 124.8 ± 10.7, 123.5 ± 13.6, and 122.8 ± 13.1 ms; P = 0.57), whereas non-affected eyes with normal latency at baseline deteriorated slightly (P = 0.001). A subgroup with more homogeneously defined follow-up periods confirmed this observation. Non-affected eyes selected for stability (difference <5 ms) between first and second recording deteriorated (normal baseline, n = 66 eyes, P = 0.013) or remained stable (prolonged baseline, n = 18 eyes, 95% confidence interval of change –5.42 to +6.89 ms, P = 0.805).

Conclusion

Prolonged P100 latencies in eyes never affected by clinical ON remain stable and thus can be used as surrogate outcome measure for remyelination trials.

Key Words: clinical trials, multiple sclerosis, outcome measure, remyelination, visual evoked potentials

First published on August 13, 2008, doi:10.1177/1352458508095731

Multiple Sclerosis 2009;15:68.

A more recent version of this article appeared on January 1, 2009
This version was published on November 21, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?